Aeolus Announces Process Improvements and Positive 18 Month Stability Results for AEOL 10150 in New Formulation
February 13, 2014 07:30 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Feb 13, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)
90% reduction in manufacturing cost of drug substance achieved;...
Aeolus Announces Publication of Data Demonstrating Efficacy of AEOL 10150 in Animal Model of Lung Radiation Exposure; Models Developed for Pivotal Efficacy Studies
February 10, 2014 07:30 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Feb 10, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)
Three papers published in Health Physics, Volume 106, Number 1 (January 2014)
...
Aeolus Receives Orphan Drug Designation for AEOL 10150 From U.S. FDA
January 23, 2014 10:52 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Jan 23, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with...
Aeolus Announces Fiscal Year 2013 Financial Results
December 23, 2013 08:00 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Dec 23, 2013) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with...
Aeolus Files Application for New Patent on AEOL 10150
December 05, 2013 11:14 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Dec 5, 2013) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)
Filing covers synthesis, formulation and pharmaceutical composition
...
Radiation Detection, Monitoring & Safety Market for Nuclear Power Plants, Homeland Security & Defense, Manufacturing Industry
November 14, 2013 09:48 ET
|
Research and Markets
Trends & Global Forecasts to 2017, Nov. 14, 2013 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/cv3wpm/radiation)
has announced the addition of the...
Radiation Therapy Equipment - Global Strategic Business Report 2012-2018
November 07, 2013 09:40 ET
|
Research and Markets
Dublin, Nov. 7, 2013 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/2r75m2/radiation_therapy)
has announced the addition of the
"Radiation Therapy Equipment -...
Aeolus' AEOl 10150 Significantly Improves Survival and Protects Lungs in Mice Exposed to Lethal Radiation
October 29, 2013 08:00 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Oct 29, 2013) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)
Optimal dose of AEOL 10150 improved survival by four times over untreated...
Radiation Cured Products: UV Cured Powder Coatings Emerge Victorious in Eco-Friendly Race
October 24, 2013 07:27 ET
|
Research and Markets
Dublin, Oct. 24, 2013 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/f2pszs/radiation_cured)
has announced the addition of the
"Radiation Cured Products - Global...
BARDA Exercises $6.0MM in Additional Contract Funding for Development of AEOL-10150 as Treatment for Acute Radiation Syndrome
September 17, 2013 13:30 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Sep 17, 2013) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)
BARDA exercise options valued at $6.0 million effective September 16, 2013...